Dakrin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dakrin

What is Dakrin? Identity and Purpose Overview

Property Description
Active ingredient Miconazole Nitrate
Form Cream, Oral Gel, Tincture, Solution, Suppository
Pharmacological class Azole Antifungal Agent
Common use Countering fungal and yeast infections
Origin Synthetic Imidazole Derivative

Miconazole Nitrate: Defining the Antifungal Agent

Dakrin is a pharmaceutical preparation fundamentally defined by its active chemical substance, Miconazole Nitrate, which is classified as a broad-spectrum antifungal agent. This medicine is structurally identified as a synthetic imidazole derivative, placing it within the specialized azole antifungal group. Miconazole possesses clinical effectiveness against a wide range of common fungal pathogens, including Candida species. It is characterized as a fundamental treatment option, signifying its reliable and critical role in addressing common fungal pathogens.


Composition and Versatile Dosage Forms

Dakrin is typically formulated as a single-ingredient product, with Miconazole Nitrate serving as the sole therapeutic component. This active ingredient is prepared in diverse physical forms to ensure optimal delivery to the infection site. While often recognized in its cream base for skin infections, the compound's versatility extends to formulations like a specialized oral gel for mucous membranes, and alcoholic solutions or tinctures. This extensive range of presentations facilitates administration via various routes, including topical and oral application, allowing for targeted use across different localized fungal conditions. For instance, the oral gel formulation is frequently used for treating infants and children with oral candidiasis.


General Purpose and Fungicidal Action

The general purpose of Dakrin is to address and resolve infections caused by pathogenic fungi and yeasts. It achieves this by executing a direct fungicidal action, actively destroying the fungal cells rather than merely arresting their growth. This efficacy is based on Miconazole's established mechanism: interference with the synthesis of ergosterol, a critical building block necessary for the structural integrity of the fungal cell wall. This action disrupts the cell wall, which is the key mechanism by which the medication resolves the underlying microbial cause of the infection.

Regulatory References

  1. Miconazole entry on WHO Essential Medicines List
  2. WHO Essential Medicines List

What side effects are possible with Dakrin?

Possible Side Effects and Safety Information

The safety profile of Miconazole Nitrate (Dakrin) is defined by adverse reactions classified according to their frequency and the body systems they affect, as documented in regulatory sources.

Frequency-Classified Adverse Reactions

The most commonly reported adverse events are local reactions, particularly with topical and oral applications. Officially documented frequencies include:

Classification Examples of Documented Reactions
Common Burning sensation, pruritus (itching), irritation, and redness (erythema) at the application site.
Uncommon Allergic contact dermatitis, skin rash, and local discomfort.
Rare Anaphylactic reaction and severe hypersensitivity.
Frequency Not Known Very rare but severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

System-Organ Classes and Serious Safety Concerns

Adverse reactions are organized into System-Organ Classes (SOCs) in prescribing information. While Skin and Subcutaneous Tissue Disorders are most frequently involved, other systems are also documented:

  • Gastrointestinal Disorders: Associated with oral formulations, side effects may include nausea, vomiting, and abdominal discomfort.
  • Hepatobiliary Disorders: Serious hepatic injury, including toxic hepatitis, has been documented in regulatory labels.
  • Immune System Disorders: Covers potential reactions such as hypersensitivity and anaphylaxis.

Population and Contextual Safety Notes

Official documents highlight specific safety considerations:

  • Pediatric Population: The potential for systemic absorption, particularly with the oral gel, is a consideration, and the risk of toxic hepatitis has been noted in infants and children.
  • Time-Related Pattern: Local adverse events like burning and irritation are often reported as being more frequent at the initiation of therapy and may lessen with continued use.
  • Safety Restriction: Miconazole is formally contraindicated in individuals with a known hypersensitivity to the active substance or to other imidazole derivatives.

This structure, derived entirely from official regulatory data, defines the formal safety boundaries and known risk characteristics of the medicine.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Dakrin (Miconazole Nitrate)


Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations Excessive use of topical formulations may result in local skin irritation, including redness, swelling, or a burning sensation. Accidental oral ingestion of large quantities may lead to stomach irritation, vomiting, and diarrhea.
Physiological systems affected (as stated in label) Gastrointestinal system (following ingestion) and Integumentary system (from excessive topical use).
Dose-related or exposure-related factors (if applicable) Accidental oral ingestion of large quantities or excessive topical use are the circumstances associated with documented symptoms.
Population-specific overdose notes (if applicable) No explicit population-specific considerations are documented within the overdose section.
Emergency-response statements (as written in official documents) A specific antidote is not available. Treatment required is symptomatic and supportive. Gastric lavage is described as a procedural measure for certain ingested formulations.
When immediate medical help is required (label-derived phrasing only) In cases of accidental oral ingestion, seek medical help or contact a Poisons Information Center immediately.

Overdose classifications (high-level)

Element Official Regulatory Statement
Severity classification (as defined in official documents) The effects are primarily local and transient (topical) or require immediate supportive medical attention (ingestion).
Regulatory basis (EMA / FDA / etc.) Summaries of Product Characteristics (SmPC) and U.S. FDA Prescribing Information.
Overdose-context constraints (as defined in official documents) Management is constrained by the documented absence of a specific antidote.

Resulting overdose structure

  • Accidental oral ingestion requires the immediate contact of medical professionals or a Poisons Information Center.
  • Overdose manifestations include gastrointestinal distress and local skin irritation.
  • Management is defined as symptomatic and supportive treatment.
  • The regulatory documents explicitly state that a specific antidote is not available.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile for Dakrin primarily by expected gastrointestinal distress following accidental ingestion of large quantities and localized irritation from excessive topical application. These scenarios mandate the immediate seeking of supportive medical attention, as the official labeling confirms that no specific antidote exists to reverse the effects.

Therapeutic Uses of Dakrin

Quick Facts: Uses of Dakrin

  • May be prescribed for the management of tinea pedis (athlete's foot).
  • An option for the treatment of cutaneous candidiasis (skin yeast infections).
  • Used in therapeutic regimens for fungal infections of the skin, such as tinea corporis (ringworm).

What Dakrin Treats: Main Uses and Benefits

Dakrin is a medication indicated for the management of specific fungal infections of the skin and nails. Its primary function involves addressing dermatophyte and yeast infections. The medication is an option often considered in therapeutic strategies to help manage symptoms associated with tinea infections, including tinea pedis (athlete's foot), tinea corporis (ringworm), and tinea cruris (jock itch).

The medication is also used for the topical treatment of cutaneous candidiasis, which involves yeast infections of the skin. Furthermore, Dakrin may be considered for tinea versicolor and certain instances of nail fungal infections. The overall intent of treatment is to help resolve the infection and mitigate associated discomfort. Before initiating therapy, patients should discuss their specific condition and regimen details with a healthcare professional to ensure appropriate use.

Eligibility and Restrictions for Use

Dakrin (Miconazole oral gel) is not suitable for all individuals. The official regulatory documents strictly define who is eligible to use this medicine and who is prohibited from using it (contraindicated).

Populations Who Must Not Use Dakrin (Contraindications)

The medicine is formally contraindicated for the following populations and conditions:

  • Infants under the age of 4 months (some regulations specify under 6 months) or those with an insufficiently developed swallowing reflex, due to the significant risk of choking.
  • Individuals with a known hypersensitivity or allergy to miconazole, other imidazole antifungals, or any of the product's excipients.
  • Patients diagnosed with liver dysfunction.

Contraindicated with Specific Medications

Dakrin is strictly contraindicated when co-administered with a long list of specific medications, including certain oral midazolam and triazolam, cisapride, pimozide, quinidine, dofetilide, astemizole, terfenadine, mizolastine, and HMG-CoA reductase inhibitors (statins) like simvastatin and lovastatin. Additionally, use is often prohibited with oral anticoagulants such as warfarin, or requires very careful monitoring and titration when supervised by a healthcare professional.

Use in Pregnancy and Lactation

Dakrin should be avoided if possible during pregnancy, as official documents recommend weighing potential hazards against expected therapeutic benefits. Caution is advised for nursing mothers, as it is not definitively known if miconazole is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dakrin (miconazole) has a comprehensive interaction profile primarily structured around its ability to inhibit specific liver enzymes, particularly Cytochrome P450 3A4 (CYP3A4) and 2C9 (CYP2C9). This inhibition increases the concentration and effect of co-administered medicines that are metabolized by these enzymes.

Contraindicated Combinations

The co-administration of Dakrin is strictly contraindicated with medicinal products where increased exposure poses a severe risk. These include:

  • Oral Anticoagulants: Such as Warfarin, due to a high risk of increased bleeding.
  • QT-Prolonging Agents: Including specific antihistamines and antiarrhythmics (e.g., astemizole, pimozide, quinidine), due to the risk of severe cardiac events.
  • Certain Sedatives: Including specific benzodiazepines (e.g., oral midazolam, triazolam).

Combinations Requiring Caution

Caution is required with other drugs metabolized by CYP3A4 or CYP2C9. These interactions often necessitate dose adjustment or close monitoring, as officially stated in regulatory documents:

  • Immunosuppressants: Such as Cyclosporine, Tacrolimus, and Sirolimus.
  • Oral Hypoglycemics (Sulfonylureas): Potential for enhanced blood-glucose-lowering effects.
  • HMG-CoA Reductase Inhibitors (Statins): Specifically Simvastatin and Lovastatin.

Additionally, drugs that increase gastric pH, such as antacids, may reduce the absorption of Dakrin and require separated administration times. Antagonism has also been reported with the antifungal agent Amphotericin B.

Mechanism of Action

The Fungicidal Mechanism of Dakrin

The mechanism involves a specific fungicidal action, fundamentally targeting the unique biochemical machinery of the fungal cell, leading to the final cellular outcome of the fungicidal process.


Targeting the Ergosterol Biosynthesis Pathway

The drug's primary action involves the targeted inhibition of a key fungal enzyme, lanosterol 14α-demethylase (CYP51). By binding to this enzyme, Miconazole arrests the conversion of lanosterol into ergosterol, which is vital for the fungal cell membrane's structure. This enzymatic blockade is the starting point of a cascade that disrupts the cellular balance (homeostasis) of sterols.


Inducing Fungal Cell Membrane Failure

The lack of ergosterol, combined with the forced accumulation of toxic, intermediate sterols within the cell, critically compromises the membrane's integrity. This structural failure leads to an uncontrolled increase in membrane permeability, causing the leakage of essential intracellular components like potassium and amino acids. This irreversible breakdown culminates in the lysis and death of the fungal organism.


Mechanistic Constraints: Fungal Resistance

The mechanism's action can be physiologically constrained when the fungus develops adaptive strategies, primarily involving genetic alterations to the CYP51 enzyme that reduce Miconazole binding. Additionally, the fungus may activate efflux pumps—specialized membrane transporters that actively expel the drug—thereby lowering the effective drug concentration at the site of the target enzyme.

Dosage and Administration Information

How Dakrin is Used

Dakrin (Miconazole Nitrate) is administered through specific local routes, depending on the pharmaceutical form, with dosage and duration defined by standard pharmaceutical parameters.


Official Routes and Administration Regimens

The medicine is used topically, oromucosally, or intravaginally. The regimen is fixed and non-adjustable outside of these parameters:

Form and Route Standard Adult Dosing Typical Course Duration Administration Timing/Constraint
Topical Cream (2%) Apply a thin layer 2 times daily to affected areas. 2 to 4 weeks (e.g., for tinea infections). Do not apply an occlusive dressing unless instructed.
Vaginal Suppository 100 mg once daily, 200 mg once daily, or single 1200 mg dose. 7, 3, or 1 consecutive day(s), respectively. Typically inserted at bedtime.
Buccal Tablet (50 mg) Apply 1 time daily to the upper gum (canine fossa). 14 consecutive days (for adults ≥ 16 years). Do not crush, chew, or swallow the tablet; alternate application sides daily.
Oral Gel (2%) 2.5 mL applied 4 times daily. 7 to 14 days or until 1 week after symptoms resolve. Use after meals; hold in mouth as long as possible before swallowing.

Population-Specific Instructions

For Oral Gel use in infants aged 6 months to 2 years, the standard dose is 1.25 mL four times daily. Due to its consistency, the gel should be administered in small portions and placed only in the front of the mouth to avoid pharyngeal obstruction. No specific dosage adjustments are stated for adults with renal or hepatic impairment due to the drug's localized nature.

Recent Clinical Evidence

The research base for Miconazole Nitrate (Dakrin) includes Randomized Controlled Trials (RCTs) and systematic reviews exploring its use in common skin fungal and yeast infections. These studies examined outcomes such as mycological cure (absence of fungus/yeast) and clinical improvement (changes in symptoms like redness and scaling). The trials typically enroll adults and compare the topical formulation against a non-active vehicle or another topical medication studied for similar purposes. Studies reported patterns of change in symptoms over the short-term study duration.

For mucosal infections like oral thrush and vaginal yeast infections, specialized controlled clinical trials assessed targeted formulations. Research examined the Overall Therapeutic Endpoint, which combines the microbiological status with the assessed clinical status. Trials described patterns related to changes in visible lesions and symptom intensity for these localized conditions. Findings indicate that outcomes related to non-C. albicans yeast species may vary compared to the more common C. albicans strain, with findings for the less common strains sometimes being uncertain.

The core efficacy research for Dakrin is primarily designed to assess short-term symptom changes over periods lasting only a few weeks. For all indications, research highlights that follow-up durations were limited in most primary studies. This means there is limited information to provide insight into long-term relapse rates or the durability of the observed changes; long-term effects are not fully established. Furthermore, while Miconazole Nitrate was evaluated in specific patient populations, such as infants and adults with diabetes, data for certain complex groups remain insufficient, and the results apply only to the populations studied.

Frequently Asked Questions (FAQ)

Common questions about Dakrin (FAQ)


Q: Is Dakrin a prescription-only medication, or can it be bought over-the-counter?

Miconazole, the active ingredient in Dakrin, is available in both prescription and over-the-counter (OTC) forms, according to official product information. Whether a specific product is OTC or prescription depends on the formulation, strength, and the intended use.


Q: Are there different forms of Dakrin available (e.g., cream, gel, tablet)?

Yes, regulatory documents show that Dakrin (miconazole) is produced in several different forms. These include a topical cream, oral gel, vaginal suppository, buccal tablet, tincture, and solution. This variety allows the medicine to be optimally delivered to different localized infection sites.


Q: Can Dakrin be used for infections outside of the mouth or skin?

Official regulatory documents define Dakrin's approved routes of administration as topical (skin), oromucosal (mouth), and intravaginal. Regulatory documents indicate that the medicine's approvals are for localized uses and do not include treatment for deep systemic (blood-borne) fungal infections or sites outside of these specified localized areas.


Q: How does the effectiveness of Dakrin compare to other antifungal medicines?

In clinical trials for certain localized infections, Dakrin's active ingredient has been evaluated against other antifungal agents, such as clotrimazole. Studies generally assess effectiveness based on outcomes such as achievement of mycological cure and observed clinical improvement, typically comparing the drug to a non-active substance or other localized treatments.


Q: Is it normal to feel a mild burning or tingling sensation when first applying Dakrin?

Regulatory reports indicate that a burning sensation, itching, irritation, and redness are listed as common side effects for topical and oral forms. Official product information notes that these local reactions are often more frequent when therapy is first started.


Q: Are there any specific foods or drinks to avoid while using Dakrin?

The product information for the oral gel generally advises administration after meals and recommends holding the gel in the mouth as long as possible before swallowing. Separately, drugs that increase stomach pH (like antacids) may reduce absorption and should be taken at a different time.


Q: What makes Dakrin's oral gel formulation different from a lozenge or capsule?

The oral gel is specially formulated to be smeared onto the affected areas inside the mouth. This localized application is designed to ensure a long contact time, which is essential for treating mucous membrane infections. This differs from a capsule, which is swallowed immediately, or a tablet designed to adhere or dissolve.


Q: Can elderly patients safely use Dakrin?

For localized forms like topical and vaginal preparations, no specific dosage adjustments are stated in the label based on age-related changes to renal or hepatic function, due to the drug's limited systemic absorption. Official information on certain formulations may note that specific geriatric data is limited or unavailable.


Q: Does Dakrin lose its effectiveness if the treatment course is stopped too soon?

Official guidelines specify a full course duration for treatment, often lasting a set period even after symptoms clear. Completing the full course of treatment is generally recommended to optimize the potential for achieving mycological cure and minimize the risk of the infection recurring.


Q: Is Dakrin safe for use by people with diabetes?

Official information notes a need for monitoring in patients taking certain oral diabetes medications, specifically sulfonylureas, as the active ingredient in Dakrin can potentially enhance the blood-glucose-lowering effect of these drugs. Clinical trials for oral infections have included adults with diabetes.


Q: Does Dakrin affect the efficacy of oral contraceptives (birth control pills)?

Because Dakrin's active ingredient can inhibit the CYP3A4 enzyme, it has the potential to alter the levels of certain hormonal contraceptives. Official documents recommend evaluating the potential for this drug interaction, although specific contraindications may not always be listed for the localized forms.


Q: How soon after a missed dose of Dakrin should the next dose be taken?

Regulatory patient information often suggests that if a dose is missed, the next dose can be administered when remembered. However, if the time for the next scheduled dose is near, the missed dose is typically skipped. Patients are generally advised on the product label to not take a double dose to compensate for a forgotten one.


Q: How long does Dakrin stay in your system after you stop taking it?

For the small amount of the drug that is systemically absorbed, the active ingredient has a reported half-life of approximately 24 hours. This time frame represents how long it takes for half of the drug to be eliminated from the body following systemic administration.


Q: Why is it important to continue using Dakrin even after symptoms disappear?

Regulatory documents define a full course duration (for example, until one week after symptoms resolve). The purpose of this full duration is to ensure the destruction of all fungal cells to optimize the potential for long-term clearance and prevent the infection from returning.


Q: Is Dakrin safe for use during pregnancy or while breastfeeding?

Official information advises that Dakrin should generally be avoided if possible during pregnancy; its use during this time involves weighing the potential benefits against the risks. Caution is advised during nursing, as it is not definitively known if the drug passes into human milk.


Q: Does using Dakrin make you more sensitive to sunlight?

The official regulatory documents and safety profiles for the active ingredient in Dakrin do not list photosensitivity (increased sensitivity to sunlight) as a common or specific adverse reaction.


Q: Does Dakrin have any side effects related to taste changes or dry mouth?

Yes, regulatory documents for oral formulations (gel and buccal tablet) list side effects that affect the mouth. These include reports of dry mouth, dysgeusia (altered taste), and loss of taste.


Q: What is the difference between Dakrin Oral Gel and Dakrin Cream?

The primary difference lies in their intended use and administration. The Oral Gel is specifically formulated for application inside the mouth to treat mucous membrane infections. The Cream is a topical formulation meant only for use on the skin to treat cutaneous fungal infections.


Q: What should I do if I accidentally swallow a small amount of the topical Dakrin cream or gel?

Accidental ingestion of a small amount of the active ingredient from a tube of topical cream is generally considered unlikely to cause serious toxic effects. However, in cases of suspected overdose or if a large amount is ingested, official safety guidance suggests seeking advice from a poison control center or healthcare provider.


Q: How does Dakrin oral gel interact with dentures in patients with oral thrush?

Regulatory guidance specifies that, for effectiveness, dental prostheses (dentures) should typically be managed, such as by removal at night and application of the gel to the contact surfaces. This helps ensure the medication reaches all infected areas.


Q: Are there any known issues with Dakrin and liver function?

Yes. Dakrin is formally contraindicated (should not be used) in patients with a known history of liver dysfunction. Serious hepatic injury, including toxic hepatitis, has been documented as a possible adverse event, particularly in infants and children.


Q: Is Dakrin used for systemic fungal infections or only localized ones?

According to official therapeutic indications, Dakrin is intended for the treatment of localized fungal infections, such as those affecting the skin, mouth, or vagina. It is not approved or indicated for treating widespread or systemic (deep-tissue or blood-borne) fungal infections.


Q: Can Dakrin affect blood sugar levels in people taking oral diabetes medications?

Yes. Because Dakrin can interact with certain oral hypoglycemics (like sulfonylureas), there is a possibility of an enhanced blood-glucose-lowering effect. Patients taking these medications may require closer monitoring.


Q: What are the early signs that Dakrin is starting to work?

Clinical trials evaluate the medicine’s effectiveness based on clinical improvement. Changes observed in clinical trials, such as a decrease in redness, scaling, or the resolution of visible lesions, are noted as indicators of clinical improvement.


Q: Does Dakrin contain alcohol, and is the amount significant?

The specific composition depends on the formulation; for instance, the solution/tincture forms of miconazole often contain alcohol. The specific composition is detailed on the official product labeling, including the excipients (inactive ingredients), which identifies the presence and amount of alcohol in a given formulation.


Q: Are there any reported cases of drug resistance to Dakrin?

The active ingredient, miconazole, has been in clinical use for an extended time. Official sources indicate that resistance to miconazole among common susceptible fungal organisms is generally considered to be relatively low.


Q: Why is Dakrin sometimes used for infections of the gut as well as the mouth?

The oral gel is administered to the mouth but is eventually swallowed. This allows the medicine to act locally on fungal infections that may extend down the throat into the esophagus or upper gastrointestinal tract, which is an intended use in regulatory indications for oral candidiasis.


Q: Is Dakrin effective against bacterial infections, or only fungal ones?

Dakrin is primarily classified as an azole antifungal agent, meaning its main purpose is to destroy fungi and yeasts. The primary indication is to treat fungi and yeasts, and its activity is focused on the fungal mechanism.

How should Dakrin be stored and disposed of?

How to Store and Dispose of Daktarin (Miconazole)

Official regulatory guidelines strictly define the conditions necessary for storing and disposing of Daktarin to maintain its stability and ensure safety.

Storage Requirements

Classification Requirement
Temperature Range Store the product below 30 C (or at or below 25 C).
Environmental Control The medicine must be protected from light and heat and must not be frozen.
Container Rule The container must be kept well closed to prevent contamination or degradation.
Child Safety The product must be kept out of the sight and reach of children.

Stability and Disposal

The unopened product has a stated shelf-life, and it must not be used past the expiry date. Once the tube is first opened, the medicine must be discarded after one episode of treatment is completed. For disposal, unused or expired Daktarin must be handled in accordance with local requirements, which often involves returning it to a pharmacist for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dakrin found in:

A-Z Index: